2025-10-29 09:02:41
Presenters: Draelos ZD,1 Moradi A,2 Smathers A3
Affiliations: 1Dermatology Consulting Services, PLLC, High Point, NC; 2Moradi M.D., Vista, CA; 3skinbetter science, a Dermatological Beauty Brand of L’Oréal USA, Inc.
Objectives: Evaluate the safety, tolerability and efficacy of an enhanced serum containing plant adaptogens (MYS-EDS) in peri- and postmenopausal females.
Methods: A multi-center, open-label trial enrolled female subjects (aged 47-67 years) with menopause-related visible skin changes. Investigators assessed lines/wrinkles, elastosis/crepiness, skin quality parameters, TEWL, skin hydration, and safety. Subjects completed self-assessment questionnaires; Adverse Events (AEs) were captured throughout the study.
Results: Fifty-five subjects were enrolled; 53 subjects completed the study (55 years, mean age). Most subjects were non-Hispanic (92%) and FST I-III (78%); 29% were perimenopausal, 71% were post-menopausal. Significant improvements from baseline were observed at week 16 in elasticity (32%) and lines/wrinkles (22%; all p<.001), as well as in erythema (65%), dullness (49%), texture/ roughness (53%), pore size (23%) and uneven pigmentation (28%; all p<.0001). Improvements in skin hydration and TEWL measurements were significant after initial application of study product (35%, p<.0001; n=44) with sustained improvement through 16 weeks (60%, p<.0001). Subjects reported high levels of satisfaction as early as 4 weeks. At 16 weeks, 94% of subjects reported skin looks and feels more hydrated, 92% reported skin looks rejuvenated and feels revitalized, and 90% agreed skin looks plumper, revived and feels reenergized. There was 1 possibly-related Adverse Event that resolved without sequelae; no subject discontinued the study or product due to an AE.
Conclusion: Twice-daily use of MYS-EDS in peri- and post-menopausal subjects demonstrated significant reductions in the appearance of elastosis and line/wrinkles from baseline over 16 weeks. Subjects reported improvements in the overall quality of their skin.
Disclosures: AS is an employee of skinbetter science.
Funding: This study was sponsored by skinbetter science, a Dermatological Beauty Brand of L’Oréal USA, Inc.
©Matrix Medical Communications. View All Articles.